Deferoxamine mesylate

Biological Activity

Deferoxamine mesylate is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate acts as a chelating agent used to remove excess iron from the body. Deferoxamine is also an inhibitor of iron death that stabilizes HIF-1α expression and improves HIF-1α activity under hypoxia and hyperglycemia in vitro.

Please do not prepare stock solutions with normal saline or PBS, as precipitation may occur.

Product Citations

• 

  Mol Cell. 2024 Sep 14.

  Hydrogen sulfide-mediated persulfidation regulates homocysteine metabolism and enhances ferroptosis in non-small cell lung cancer
  Deferoxamine mesylate purchased from AbMole

• 

  Adv Sci (Weinh). 2023 May;10(15):e2207224.

  Hypoxia Drives Material-Induced Heterotopic Bone Formation by Enhancing Osteoclastogenesis via M2/Lipid-Loaded Macrophage Axis
  Deferoxamine mesylate purchased from AbMole

• 

  Asian Journal of Pharmaceutical Sciences. 2023 Nov.

  Mechanistic engineering of celastrol liposomes induces ferroptosis and apoptosis by directly targeting VDAC2 in hepatocellular carcinoma
  Deferoxamine mesylate purchased from AbMole

• 

  Oxid Med Cell Longev. 2023 Jan 14;2023:6896790.

  Curcumin Induces Ferroptosis in Follicular Thyroid Cancer by Upregulating HO-1 Expression
  Deferoxamine mesylate purchased from AbMole

• 

  Cancer Cell Int. 2023 Jan 13;23(1):5.

  Heat shock protein 27 defciency promotes ferrous ion absorption and enhances acyl-Coenzyme A synthetase long-chain family member 4 stability to promote glioblastoma cell ferroptosis
  Deferoxamine mesylate purchased from AbMole

• 

  SSRN. 2023 Feb 3.

  Aerobic Exercise-Induced HIF-1α Overexpression Ameliorates Heart Failure Via the Pyruvate-Lactic Acid Axis
  Deferoxamine mesylate purchased from AbMole

• 

  Acta Pharm Sin B. 2022 May;12(5):2300-2314.

  Celastrol induces ferroptosis in activated HSCs to ameliorate hepatic fibrosis via targeting peroxiredoxins and HO-1
  Deferoxamine mesylate purchased from AbMole

• 

  Chem Biol Interact. 2022 Nov 14;369:110262.

  Trabectedin induces ferroptosis via regulation of HIF-1α/IRP1/TFR1 and Keap1/Nrf2/GPX4 axis in non-small cell lung cancer cells
  Deferoxamine mesylate purchased from AbMole

• 

  Anat Rec (Hoboken). 2020 Jan 21.

  Resibufogenin inhibited colorectal cancer cell growth and tumorigenesis through triggering ferroptosis and ROS production mediated by GPX4 inactivation
  Deferoxamine mesylate purchased from AbMole

• 

  Metallomics. 2018 Aug 24.

  Iron depletion participates in the suppression of cell proliferation induced by lipin1 overexpression.
  Deferoxamine mesylate purchased from AbMole

Customer Product Validations & Biological Datas

	Source	The Royal Society of Chemistry (2018 Aug). Figure 1. Deferoxamine (Abmole Bioscience)
	Method	Cell viability assay
	Cell Lines	Empty vector cells
	Concentrations	0-1600 mM
	Incubation Time	24, 48 and 72 h
	Results	Herein, we found that DFO inhibited the growth of human BEL7402 cells in a dose and time dependent manner.

Chemical Information

Molecular Weight	656.79
Formula	C26H52N6O11S
CAS Number	138-14-7
Solubility (25°C)	Water ≥ 100 mg/mL DMSO 90 mg/mL
Storage	Powder          -20°C   3 years ;  4°C   2 years In solvent       -80°C   6 months ;  -20°C   1 month

References

[1] Yanjiang Li, et al. PLoS One. Effects of deferoxamine on blood-brain barrier disruption after subarachnoid hemorrhage

[2] Dominik Duscher, et al. Plast Reconstr Surg. Comparison of the Hydroxylase Inhibitor Dimethyloxalylglycine and the Iron Chelator Deferoxamine in Diabetic and Aged Wound Healing

[3] Yu Y, et al. PLoS One. The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage.

[4] Jared M Fine, et al. Neurosci Lett. Intranasal deferoxamine engages multiple pathways to decrease memory loss in the APP/PS1 model of amyloid accumulation